Bortezomib Injection 3.5mg Vial, Single Dose by Somerset Pharma (RX)


Bortezomib is a chemotherapy drug (a proteasome inhibitor) used to treat certain blood cancers. It works by blocking the 26S proteasome inside cells, preventing the breakdown of proteins that trigger cell death. Cancer cells (especially myeloma cells) cannot survive when this proteasome is inhibited, so they undergo apoptosis. Brand names include Velcade® (bortezomib for injection).
Bortezomib injection is FDA-approved for adults with multiple myeloma and mantle cell lymphoma. It is often given in combination with other chemotherapy (e.g. dexamethasone, melphalan, cyclophosphamide, etc.). It may be used as initial therapy, or for relapsed/refractory disease after prior treatment.
The typical starting dose is 1.3 mg/m² of body surface area, given as either a rapid IV push (3–5 seconds) or an SC injection. Treatment schedules vary, but a common regimen is twice weekly on days 1, 4, 8, and 11 of a 21-day cycle, followed by a 10-day rest. Dose adjustments may be needed for patients with liver impairment or other factors. Your doctor will calculate the exact dose and schedule; do not change the dose on your own.
Bortezomib is given only by healthcare professionals in a clinic or hospital. Do not attempt to self-inject unless specifically trained. It can be given into a peripheral vein or via a central line. Rotating injection sites (for SC) can help reduce local irritation. Since IV and SC concentrations differ, double-check the preparation before giving any dose. Important: Bortezomib must never be administered intrathecally (into the spine) – this is contraindicated and can be fatal.
Bortezomib has several potential side effects. Some of the most common (occurring in ≥20% of patients) include:
Serious Warnings: Though less common, bortezomib can cause serious problems. These include heart failure or heart damage, severe lung problems, and a rare brain condition called Posterior Reversible Encephalopathy Syndrome (PRES), which involves headaches, vision changes, or seizures. Always report any chest pain, sudden shortness of breath, severe headache, confusion, or other alarming symptoms immediately. Bortezomib may also cause birth defects – effective birth control is essential for both men and women during treatment.
Your healthcare team will monitor you closely during bortezomib therapy:
Always follow your healthcare team’s instructions exactly. Keep all appointments and lab tests, and communicate any concerns. This information is a general guide; your doctor and pharmacist will give you detailed counseling tailored to your health needs.
Bortezomib is a chemotherapy drug (a proteasome inhibitor) used to treat certain blood cancers. It works by blocking the 26S proteasome inside cells, preventing the breakdown of proteins that trigger cell death. Cancer cells (especially myeloma cells) cannot survive when this proteasome is inhibited, so they undergo apoptosis. Brand names include Velcade® (bortezomib for injection).
Bortezomib injection is FDA-approved for adults with multiple myeloma and mantle cell lymphoma. It is often given in combination with other chemotherapy (e.g. dexamethasone, melphalan, cyclophosphamide, etc.). It may be used as initial therapy, or for relapsed/refractory disease after prior treatment.
The typical starting dose is 1.3 mg/m² of body surface area, given as either a rapid IV push (3–5 seconds) or an SC injection. Treatment schedules vary, but a common regimen is twice weekly on days 1, 4, 8, and 11 of a 21-day cycle, followed by a 10-day rest. Dose adjustments may be needed for patients with liver impairment or other factors. Your doctor will calculate the exact dose and schedule; do not change the dose on your own.
Bortezomib is given only by healthcare professionals in a clinic or hospital. Do not attempt to self-inject unless specifically trained. It can be given into a peripheral vein or via a central line. Rotating injection sites (for SC) can help reduce local irritation. Since IV and SC concentrations differ, double-check the preparation before giving any dose. Important: Bortezomib must never be administered intrathecally (into the spine) – this is contraindicated and can be fatal.
Bortezomib has several potential side effects. Some of the most common (occurring in ≥20% of patients) include:
Serious Warnings: Though less common, bortezomib can cause serious problems. These include heart failure or heart damage, severe lung problems, and a rare brain condition called Posterior Reversible Encephalopathy Syndrome (PRES), which involves headaches, vision changes, or seizures. Always report any chest pain, sudden shortness of breath, severe headache, confusion, or other alarming symptoms immediately. Bortezomib may also cause birth defects – effective birth control is essential for both men and women during treatment.
Your healthcare team will monitor you closely during bortezomib therapy:
Always follow your healthcare team’s instructions exactly. Keep all appointments and lab tests, and communicate any concerns. This information is a general guide; your doctor and pharmacist will give you detailed counseling tailored to your health needs.
You need an account to add products to your wishlist. Log in or create an account to start saving your favorites.